Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Arbutus Biopharma (ABUS) Tops Q1 EPS by 2c
May 5, 2021 7:39 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $2.11 million versus the consensus estimate of $3.31 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
... More